BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32047267)

  • 21. Splicing Characteristics of Dystrophin Pseudoexons and Identification of a Novel Pathogenic Intronic Variant in the
    Xie Z; Tang L; Xie Z; Sun C; Shuai H; Zhou C; Liu Y; Yu M; Zheng Y; Meng L; Zhang W; Leal SM; Wang Z; Schrauwen I; Yuan Y
    Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33050418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
    Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
    PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-seq analysis, targeted long-read sequencing and in silico prediction to unravel pathogenic intronic events and complicated splicing abnormalities in dystrophinopathy.
    Okubo M; Noguchi S; Awaya T; Hosokawa M; Tsukui N; Ogawa M; Hayashi S; Komaki H; Mori-Yoshimura M; Oya Y; Takahashi Y; Fukuyama T; Funato M; Hosokawa Y; Kinoshita S; Matsumura T; Nakamura S; Oshiro A; Terashima H; Nagasawa T; Sato T; Shimada Y; Tokita Y; Hagiwara M; Ogata K; Nishino I
    Hum Genet; 2023 Jan; 142(1):59-71. PubMed ID: 36048237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping.
    Matsuo M; Takeshima Y
    Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.
    Tran VK; Takeshima Y; Zhang Z; Yagi M; Nishiyama A; Habara Y; Matsuo M
    J Med Genet; 2006 Dec; 43(12):924-30. PubMed ID: 16738009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When a mid-intronic variation of DMD gene creates an ESE site.
    Trabelsi M; Beugnet C; Deburgrave N; Commere V; Orhant L; Leturcq F; Chelly J
    Neuromuscul Disord; 2014 Dec; 24(12):1111-7. PubMed ID: 25193336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skipping of an exon with a nonsense mutation in the DMD gene is induced by the conversion of a splicing enhancer to a splicing silencer.
    Zhu Y; Deng H; Chen X; Li H; Yang C; Li S; Pan X; Tian S; Feng S; Tan X; Matsuo M; Zhang Z
    Hum Genet; 2019 Jul; 138(7):771-785. PubMed ID: 31168774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuronal SH-SY5Y cells use the C-dystrophin promoter coupled with exon 78 skipping and display multiple patterns of alternative splicing including two intronic insertion events.
    Nishida A; Minegishi M; Takeuchi A; Awano H; Niba ET; Matsuo M
    Hum Genet; 2015 Sep; 134(9):993-1001. PubMed ID: 26152642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
    Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
    Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y; Yagi M; Wada H; Matsuo M
    Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.